_id
69131366ccc777a4e85d7f98
Ticker
MBX
Name
MBX Biosciences, Inc. Common Stock
Exchange
NASDAQ
Address
11711 North Meridian Street, Carmel, IN, United States, 46032
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://mbxbio.com
Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Last Close
31.6
Volume
564045
Current Price
31.66
Change
-0.99
Last Updated
2026-01-05T10:11:08.739Z
Image
data:image/webp;base64,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
Ipo Date
2024-09-13T00:00:00.000Z
Market Cap
1371765376
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9715
Sentiment Sources
2
Rating
4.6
Target Price
59.25
Strong Buy
3
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
23926000
Operating Income
-23926000
Interest Expense
-
Pretax Income
-21618000
Net Income
-21618000
Eps
-0.6321311953235976
Dividends Per Share
-
Shares Outstanding
44902302
Income Tax Expense
-
EBITDA
-21568000
Operating Margin
-
Total Other Income Expense Net
2308000
Cash
223125000
Short Term Investments
168548000
Receivables
-
Inventories
-
Total Current Assets
397502000
Property Plant Equipment
2524000
Total Assets
400076000
Payables
3768000
Short Term Debt
154000
Long Term Debt
-
Total Liabilities
12538000
Equity
387538000
Bs_currency_symbol
USD
Depreciation
50000
Change In Working Capital
531000
Cash From Operations
-21536000
Capital Expenditures
399000
Cash From Investing
17056000
Cash From Financing
187824000
Net Change In Cash
183344000
Cf_currency_symbol
USD
PE
3.9831
PB
2.793861714257699
ROE
-5.578291677203268
ROA
-5.403473340065387
FCF
-21935000
Fcf Percent
-
Piotroski FScore
1
Health Score
43
Deep Value Investing Score
6
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
23926000
Quarters > 0 > income Statement > operating Income
-23926000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-21618000
Quarters > 0 > income Statement > net Income
-21618000
Quarters > 0 > income Statement > eps
-0.6321311953235976
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
34198597
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-21568000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
2308000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
223125000
Quarters > 0 > balance Sheet > short Term Investments
168548000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
397502000
Quarters > 0 > balance Sheet > property Plant Equipment
2524000
Quarters > 0 > balance Sheet > total Assets
400076000
Quarters > 0 > balance Sheet > payables
3768000
Quarters > 0 > balance Sheet > short Term Debt
154000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
12538000
Quarters > 0 > balance Sheet > equity
387538000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-21618000
Quarters > 0 > cash Flow > depreciation
50000
Quarters > 0 > cash Flow > change In Working Capital
531000
Quarters > 0 > cash Flow > cash From Operations
-21536000
Quarters > 0 > cash Flow > capital Expenditures
399000
Quarters > 0 > cash Flow > cash From Investing
17056000
Quarters > 0 > cash Flow > cash From Financing
187824000
Quarters > 0 > cash Flow > net Change In Cash
183344000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.6321311953235976
Quarters > 0 > ratios > PB
2.793861714257699
Quarters > 0 > ratios > ROE
-5.578291677203268
Quarters > 0 > ratios > ROA
-5.403473340065387
Quarters > 0 > ratios > FCF
-21935000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
43
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
100000
Quarters > 1 > income Statement > gross Profit
-100000
Quarters > 1 > income Statement > operating Expenses
21805000
Quarters > 1 > income Statement > operating Income
-21805000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-19411000
Quarters > 1 > income Statement > net Income
-19411000
Quarters > 1 > income Statement > eps
-0.5803616743633131
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
33446385
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-21744000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
2394000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
39781000
Quarters > 1 > balance Sheet > short Term Investments
185125000
Quarters > 1 > balance Sheet > receivables
841000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
229190000
Quarters > 1 > balance Sheet > property Plant Equipment
2281000
Quarters > 1 > balance Sheet > total Assets
231522000
Quarters > 1 > balance Sheet > payables
5764000
Quarters > 1 > balance Sheet > short Term Debt
138000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
12283000
Quarters > 1 > balance Sheet > equity
219239000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-19411000
Quarters > 1 > cash Flow > depreciation
-979000
Quarters > 1 > cash Flow > change In Working Capital
918000
Quarters > 1 > cash Flow > cash From Operations
-17434000
Quarters > 1 > cash Flow > capital Expenditures
707000
Quarters > 1 > cash Flow > cash From Investing
25986000
Quarters > 1 > cash Flow > cash From Financing
1326000
Quarters > 1 > cash Flow > net Change In Cash
9878000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.5803616743633131
Quarters > 1 > ratios > PB
4.829946082129548
Quarters > 1 > ratios > ROE
-8.853807944754355
Quarters > 1 > ratios > ROA
-8.384084449857896
Quarters > 1 > ratios > FCF
-18141000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
38
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
77000
Quarters > 2 > income Statement > gross Profit
-77000
Quarters > 2 > income Statement > operating Expenses
26529000
Quarters > 2 > income Statement > operating Income
-26529000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-23880000
Quarters > 2 > income Statement > net Income
-23880000
Quarters > 2 > income Statement > eps
-0.7147050198689792
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
33412386
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-26452000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2649000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
29903000
Quarters > 2 > balance Sheet > short Term Investments
210883000
Quarters > 2 > balance Sheet > receivables
1385000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
244276000
Quarters > 2 > balance Sheet > property Plant Equipment
1600000
Quarters > 2 > balance Sheet > total Assets
245926000
Quarters > 2 > balance Sheet > payables
4245000
Quarters > 2 > balance Sheet > short Term Debt
130000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
10504000
Quarters > 2 > balance Sheet > equity
235422000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-23880000
Quarters > 2 > cash Flow > depreciation
77000
Quarters > 2 > cash Flow > change In Working Capital
600000
Quarters > 2 > cash Flow > cash From Operations
-22678000
Quarters > 2 > cash Flow > capital Expenditures
30000
Quarters > 2 > cash Flow > cash From Investing
3226000
Quarters > 2 > cash Flow > cash From Financing
4000
Quarters > 2 > cash Flow > net Change In Cash
-19448000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.7147050198689792
Quarters > 2 > ratios > PB
4.493361456278512
Quarters > 2 > ratios > ROE
-10.143487014807452
Quarters > 2 > ratios > ROA
-9.710238039084928
Quarters > 2 > ratios > FCF
-22708000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
38
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
222000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
111000
Quarters > 3 > income Statement > operating Expenses
18610000
Quarters > 3 > income Statement > operating Income
-18610000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-15586000
Quarters > 3 > income Statement > net Income
-15586000
Quarters > 3 > income Statement > eps
-0.46674990862500587
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
33392615
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-18552000
Quarters > 3 > income Statement > operating Margin
-8382.882882882883
Quarters > 3 > income Statement > total Other Income Expense Net
3024000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
49351000
Quarters > 3 > balance Sheet > short Term Investments
212798000
Quarters > 3 > balance Sheet > receivables
682000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
267286000
Quarters > 3 > balance Sheet > property Plant Equipment
1199000
Quarters > 3 > balance Sheet > total Assets
268535000
Quarters > 3 > balance Sheet > payables
5335000
Quarters > 3 > balance Sheet > short Term Debt
171000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
11093000
Quarters > 3 > balance Sheet > equity
257442000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-15586000
Quarters > 3 > cash Flow > depreciation
58000
Quarters > 3 > cash Flow > change In Working Capital
-627000
Quarters > 3 > cash Flow > cash From Operations
-16037000
Quarters > 3 > cash Flow > capital Expenditures
92000
Quarters > 3 > cash Flow > cash From Investing
-67345000
Quarters > 3 > cash Flow > cash From Financing
-132000
Quarters > 3 > cash Flow > net Change In Cash
-83514000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.46674990862500587
Quarters > 3 > ratios > PB
4.106595625033989
Quarters > 3 > ratios > ROE
-6.054179193760148
Quarters > 3 > ratios > ROA
-5.804085128567971
Quarters > 3 > ratios > FCF
-16129000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-72.65315315315316
Quarters > 3 > health Score
29
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
244000
Annuals > 0 > income Statement > gross Profit
-244000
Annuals > 0 > income Statement > operating Expenses
68194000
Annuals > 0 > income Statement > operating Income
-68194000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-61922000
Annuals > 0 > income Statement > net Income
-61922000
Annuals > 0 > income Statement > eps
-1.8543621097059935
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
33392615
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-67950000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
6272000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
49351000
Annuals > 0 > balance Sheet > short Term Investments
212798000
Annuals > 0 > balance Sheet > receivables
682000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
267286000
Annuals > 0 > balance Sheet > property Plant Equipment
1199000
Annuals > 0 > balance Sheet > total Assets
268535000
Annuals > 0 > balance Sheet > payables
5335000
Annuals > 0 > balance Sheet > short Term Debt
171000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
11093000
Annuals > 0 > balance Sheet > equity
257442000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-61922000
Annuals > 0 > cash Flow > depreciation
244000
Annuals > 0 > cash Flow > change In Working Capital
4597000
Annuals > 0 > cash Flow > cash From Operations
-54681000
Annuals > 0 > cash Flow > capital Expenditures
874000
Annuals > 0 > cash Flow > cash From Investing
-160595000
Annuals > 0 > cash Flow > cash From Financing
234104000
Annuals > 0 > cash Flow > net Change In Cash
18828000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-1.8543621097059935
Annuals > 0 > ratios > PB
3.962618330536587
Annuals > 0 > ratios > ROE
-24.05279635801462
Annuals > 0 > ratios > ROA
-23.059191539277933
Annuals > 0 > ratios > FCF
-55555000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
29
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
157000
Annuals > 1 > income Statement > gross Profit
-157000
Annuals > 1 > income Statement > operating Expenses
35311000
Annuals > 1 > income Statement > operating Income
-35311000
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-32563000
Annuals > 1 > income Statement > net Income
-32563000
Annuals > 1 > income Statement > eps
-1.022267493086674
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
31853698
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-35154000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
2748000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
30523000
Annuals > 1 > balance Sheet > short Term Investments
50153000
Annuals > 1 > balance Sheet > receivables
208000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
83465000
Annuals > 1 > balance Sheet > property Plant Equipment
665000
Annuals > 1 > balance Sheet > total Assets
84180000
Annuals > 1 > balance Sheet > payables
1391000
Annuals > 1 > balance Sheet > short Term Debt
153000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
156648000
Annuals > 1 > balance Sheet > equity
-72468000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-32563000
Annuals > 1 > cash Flow > depreciation
157000
Annuals > 1 > cash Flow > change In Working Capital
-735000
Annuals > 1 > cash Flow > cash From Operations
-31978000
Annuals > 1 > cash Flow > capital Expenditures
129000
Annuals > 1 > cash Flow > cash From Investing
-30927000
Annuals > 1 > cash Flow > cash From Financing
69218000
Annuals > 1 > cash Flow > net Change In Cash
6313000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-1.022267493086674
Annuals > 1 > ratios > PB
-13.428416320306894
Annuals > 1 > ratios > ROE
44.93431583595518
Annuals > 1 > ratios > ROA
-38.68258493703968
Annuals > 1 > ratios > FCF
-32107000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
56000
Annuals > 2 > income Statement > gross Profit
-56000
Annuals > 2 > income Statement > operating Expenses
25161000
Annuals > 2 > income Statement > operating Income
-25161000
Annuals > 2 > income Statement > interest Expense
374000
Annuals > 2 > income Statement > pretax Income
-26135000
Annuals > 2 > income Statement > net Income
-26135000
Annuals > 2 > income Statement > eps
-0.8204698870441981
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
31853698
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-25705000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-974000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
24210000
Annuals > 2 > balance Sheet > short Term Investments
18251000
Annuals > 2 > balance Sheet > receivables
142000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
44211000
Annuals > 2 > balance Sheet > property Plant Equipment
842000
Annuals > 2 > balance Sheet > total Assets
45095000
Annuals > 2 > balance Sheet > payables
976000
Annuals > 2 > balance Sheet > short Term Debt
137000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
87700000
Annuals > 2 > balance Sheet > equity
-42605000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-26135000
Annuals > 2 > cash Flow > depreciation
56000
Annuals > 2 > cash Flow > change In Working Capital
1290000
Annuals > 2 > cash Flow > cash From Operations
-23122000
Annuals > 2 > cash Flow > capital Expenditures
441000
Annuals > 2 > cash Flow > cash From Investing
-11411000
Annuals > 2 > cash Flow > cash From Financing
46063000
Annuals > 2 > cash Flow > net Change In Cash
11530000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.8204698870441981
Annuals > 2 > ratios > PB
-22.84075751437625
Annuals > 2 > ratios > ROE
61.34256542659312
Annuals > 2 > ratios > ROA
-57.95542743097904
Annuals > 2 > ratios > FCF
-23563000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Valuation > metrics > PE
3.9831
Valuation > metrics > PB
2.793861714257699
Valuation > final Score
100
Valuation > verdict
30.1% Undervalued
Profitability > metrics > ROE
-5.578291677203268
Profitability > metrics > ROA
-5.438463202700867
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.03235295635524774
Risk > metrics > Interest Coverage
-478.52
Risk > final Score
-1854
Risk > verdict
High
Liquidity > metrics > Current Ratio
101.35186129525752
Liquidity > metrics > Quick Ratio
101.35186129525752
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
31.700539178704517
Prev Valuations > 1
35.066385437214876
Prev Valuations > 2
38.93404374966011
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
23
Prev Risks > 1
19
Prev Risks > 2
35
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:10:57.364Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-06
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.63
Earnings History > 0 > eps Estimate
-0.6626
Earnings History > 0 > eps Difference
0.0326
Earnings History > 0 > surprise Percent
4.92
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-07
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.58
Earnings History > 1 > eps Estimate
-0.7632
Earnings History > 1 > eps Difference
0.1832
Earnings History > 1 > surprise Percent
24.0042
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-13
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.71
Earnings History > 2 > eps Estimate
-0.7711
Earnings History > 2 > eps Difference
0.0611
Earnings History > 2 > surprise Percent
7.9237
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-17
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.47
Earnings History > 3 > eps Estimate
-0.5864
Earnings History > 3 > eps Difference
0.1164
Earnings History > 3 > surprise Percent
19.8499
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-07
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-2.78
Earnings History > 4 > eps Estimate
-2.7178
Earnings History > 4 > eps Difference
-0.0622
Earnings History > 4 > surprise Percent
-2.2886
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-28
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
-11.47
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-11.47
Earnings History > 5 > surprise Percent
-
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AMBX Biosciences (NASDAQ:MBX) Shares Down 6.8% - Here's What Happened MarketBeat
Read more →Assessing MBX Biosciences (MBX) Valuation After Guggenheim’s Supportive Obesity Drug Updates simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$59.25
Analyst Picks
Strong Buy
3
Buy
2
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of MBX Biosciences, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.63
EPS Estimate
-0.6626
EPS Difference
0.0326
Surprise Percent
4.92%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.